Trichostatin A, sodium butyrate, and 5-aza-2′-deoxycytidine alter the expression of glucocorticoid receptor α and β isoforms in Hut-78 T- and Raji B-lymphoma cell lines

Biomedicine and Pharmacotherapy

Volumn 61, Issue 7, 2007, Pages 451-454

  Piotrowska, H ^a   Jagodzinski, P P ^a  

^a POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

Author keywords

Epigenetic factors; Glucocorticoid receptor; Glucocorticoids

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; BUTYRIC ACID; GLUCOCORTICOID RECEPTOR ALPHA; GLUCOCORTICOID RECEPTOR BETA; TRICHOSTATIN A;

ARTICLE; CONTROLLED STUDY; EPIGENETICS; HUMAN; HUMAN CELL; LYMPHOMA CELL; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAJI CELL; REAL TIME POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; AZACITIDINE; BLOTTING, WESTERN; BUTYRATES; CELL LINE, TUMOR; ELECTROPHORESIS, POLYACRYLAMIDE GEL; ENZYME INHIBITORS; EPIGENESIS, GENETIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; HYDROXAMIC ACIDS; LYMPHOMA; POLYMERASE CHAIN REACTION; RECEPTORS, GLUCOCORTICOID; REVERSE TRANSCRIPTION;

EID: 34547738410     PISSN: 07533322     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biopha.2007.03.007     Document Type: Article

References (34)

1. Leung D.Y.M., and Bloom J.W. Update on glucocorticoid action and resistance. J Allergy Clin Immunol 111 (2003) 3-22
2. Almawi W.Y., Abou Jaoude M.M., and Li X.C. Transcriptional and post-transcriptional mechanisms of glucocorticoid antiproliferative effects. Hematol Oncol 20 (2002) 17-32
3. Barnes P.J. Anti-inflammatory actions of glucocorticoids: molecular mechanisms. Clin Sci (Lond) 94 (1998) 557-572
4. Naclerio R.M. The pathophysiology of allergic rhinitis: impact of therapeutic intervention. J Allergy Clin Immunol 82 (1988) 927-934
5. Riccardi C., Bruscoli S., and Migliorati G. Molecular mechanisms of immunomodulatory activity of glucocorticoids. Pharmacol Res 45 (2002) 361-368
6. Hayden M.S., West A.P., and Ghosh S. NF-kappaB and the immune response. Oncogene 25 (2006) 6758-6780
7. Karin M., Cao Y., Greten F.R., and Li Z.W. NF-kappaB in cancer: from innocent bystander to major culprit. Nat Rev Cancer 2 (2002) 301-310
8. Scheinman R.I., Cogwell P.C., Lofquist A.K., and Baldwin A.S. Role of transcriptional activation of IκBα in mediation of immunosuppression by glucocorticoids. Science 270 (1995) 283-286
9. De Castro M., Elliot S., Kino T., Bamberger C., Karl M., Webster E., et al. The non-ligand binding beta-isoform of the human glucocorticoid receptor (hGR beta): tissue levels, mechanisms of action, and potential physiologic role. Mol Med 2 (1996) 597-607
10. Goecke A., and Guerrero J. Glucocorticoid receptor beta in acute and chronic inflammatory conditions: clinical implications. Immunobiology 211 (2006) 85-96
11. Towers R., Naftali T., Gabay G., Carlebach M., Klein A., and Novis B. High levels of glucocorticoid receptors in patients with active Crohn's disease may predict steroid resistance. Clin Exp Immunol 141 (2005) 357-362
12. Koga Y., Matsuzaki A., Suminoe A., Hattori H., Kanemitsu S., and Hara T. Differential mRNA expression of glucocorticoid receptor alpha and beta is associated with glucocorticoid sensitivity of acute lymphoblastic leukemia in children. Pediatr Blood Cancer 45 (2005) 121-127
13. Shahidi H., Vottero A., Stratakis C.A., Taymans S.E., Karl M., Longui C.A., et al. Imbalanced expression of the glucocorticoid receptor isoforms in cultured lymphocytes from a patient with systemic glucocorticoid resistance and chronic lymphocytic leukemia. Biochem Biophysics Res Commun 254 (1999) 559-565
14. Lee S.C., Bottaro A., and Insel R.A. Activation of terminal B cell differentiation by inhibition of histone deacetylation. Mol Immunol 39 (2003) 923-932
15. Weisenberger D.J., Velicescu M., Cheng J.C., Gonzales F.A., Liang G., and Jones P.A. Role of the DNA methyltransferase variant DNMT3b3 in DNA methylation. Mol Cancer Res 2 (2004) 62-72
16. Chomczynski P. Sacchi N Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 162 (1987) 156-159
17. Szabo A., Perou C.M., Karaca M., Perreard L., Quackenbush J.F., and Bernard P.S. Statistical modeling for selecting housekeeper genes. Genome Biol 5 (2004) R59
18. Yoshida M., Furumai R., Nishiyama M., Komatsu Y., Nishino N., and Horinouchi S. Histone deacetylase as a new target for cancer chemotherapy. Cancer Chemother Pharmacol 48 (2001) 20-26
19. Finnin M.S., Donigian J.R., Cohen A., Richon V.M., Rifkind R.A., Marks P.A., et al. Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors. Nature 401 (1999) 188-193
20. Marks P.A., Richon V.M., and Rifkind R.A. Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells. J Natl Cancer Inst 92 (2000) 1210-1216
21. Vigushin D.M., Ali S., Pace P.E., Mirsaidi N., Ito K., Adcock I., et al. Trichostatin A is a histone deacetylase inhibitor with potent antitumor activity against breast cancer in vivo. Clin Cancer Res 7 (2001) 971-976
22. Kim M.S., Blake M., Baek J.H., Kohlhagen G., Pommier Y., and Carrier F. Inhibition of histone deacetylase increases cytotoxicity to anticancer drugs targeting DNA. Cancer Res 63 (2003) 7291-7300
23. Piacentini P., Donadelli M., Costanzo C., Moore P.S., Palmieri M., and Scarpa A. Trichostatin A enhances the response of chemotherapeutic agents in inhibiting pancreatic cancer cell proliferation. Virchows Arch 448 (2006) 797-804
24. Zhang X., Yashiro M., Ren J., and Hirakawa K. Histone deacetylase inhibitor, trichostatin A, increases the chemosensitivity of anticancer drugs in gastric cancer cell lines. Oncol Rep 16 (2006) 563-568
25. Zhou C., Qiu L., Sun Y., Healey S., Wanebo H., Kouttab N., et al. Inhibition of EGFR/PI3K/AKT cell survival pathway promotes TSA's effect on cell death and migration in human ovarian cancer cells. Int J Oncol 29 (2006) 269-278
26. Januchowski R., and Jagodzinski P.P. Trichostatin A down-regulates ZAP-70, LAT and SLP-76 content in Jurkat T cells. Int Immunopharmacol 7 (2007) 198-204
27. +T cell responses. BMC Cancer 3 (2003) 30
28. Huang N., Katz J.P., Martin D.R., and Wu G.D. Inhibition of IL-8 gene expression in Caco-2 cells by compounds which induce histone hyperacetylation. Cytokine 9 (1997) 27-36
29. Turek-Plewa J., and Jagodzinski P.P. The role of mammalian DNA methyltransferases in the regulation of gene expression. Cell Mol Biol Lett 10 (2005) 631-647
30. Chang J.G., Hsieh-Li H.M., Jong Y.J., Wang N.M., Tsai C.H., and Li H. Treatment of spinal muscular atrophy by sodium butyrate. Proc Natl Acad Sci U S A 98 (2001) 9808-9813
31. Brichta L., Hofmann Y., Hahnen E., Siebzehnrubl F.A., Raschke H., Blumcke I., et al. Valproic acid increases the SMN2 protein level: a well-known drug as a potential therapy for spinal muscular atrophy. Hum Mol Genet 12 (2003) 2481-2489
32. Fang X., Liu Z., Fan Y., Zheng C., Nilson S., Egevad L., et al. Switch to full-length of XAF1 mRNA expression in prostate cancer cells by the DNA methylation inhibitor. Int J Cancer 118 (2006) 2485-2489
33. Nissim-Rafinia M., Aviram M., Randell S.H., Shushi L., Ozeri E., Chiba-Falek O., et al. Restoration of the cystic fibrosis transmembrane conductance regulator function by splicing modulation. EMBO Rep 5 (2004) 1071-1077
34. Black D.L. Mechanisms of alternative pre-messenger RNA splicing. Annu Rev Biochem 72 (2003) 291-336